The Aesthetic Guide is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Isolagen's study results add fuel to fibroblast therapy's ability for long-lived, natural rejuvenation

Article-Isolagen's study results add fuel to fibroblast therapy's ability for long-lived, natural rejuvenation

Key iconKey Points

  • Isolagen's recently released study shows two treatments of Isolagen Therapy(tm) (Autologous Cell Therapy; ACT) improve not only the appearance of wrinkles, but also enhance skin quality
  • Complication and expense of harvesting, storing and administering patients' own cells is the primary concern surrounding Isolagen's ultimate success


EXTON, PA. — The debate regarding the significance of injecting a patient's own fibroblasts to stimulate new collagen growth that began over four years ago may finally be coming to fruition. Isolagen Inc.'s recently released study shows two treatments of Isolagen Therapy™ (Autologous Cell Therapy; ACT) improve not only the appearance of wrinkles, but also enhance skin quality. As long-time proponents contend that these results prove the use of a patient's own cells to be clinically effective and safe in addition to providing many years of correction, high cost of the therapy and competition of market leaders continues to instigate skeptical views.

Results announced from a prospective, open label, phase II study (IT-R-007) of two treatments of Isolagen Therapy in multiple facial regions ("full face") for facial wrinkles and creases in approximately 40 subjects reported improvement in the appearance of wrinkles as scored by a high percentage of both study subjects, as well as independent panel evaluators. The same results were reported regarding improvement in skin quality. At six months following the final treatment, 83 percent of subjects reported an improvement in their self-assessed score of the appearance of wrinkles. At the six-month point, the results from the independent panel evaluation of study photographs also showed improvement in the appearance of wrinkles, with the independent panel scoring improvement in over 75 percent of participants.

SKIN SCAFFOLDS

"This current study, conducted at five U.S. sites, is a strong research base that not only covers [Isolagen's impact] on wrinkles, but also skin rejuvenation. This therapy is like introducing scaffolding to the skin —a way to prepare the skin for other treatments," says Declan Daly, president and chief executive officer, Isolagen, Inc.


Autologous therapy made its debut in Europe in 2002 and was touted in a cohort study as 75 percent effective at two to four months in 59 British patients, with 100 percent of patients showing efficacy at six and 12 months. This launched international retrospective studies, which showed consistent results and led to the emergence of 14 centers around the UK and Ireland to provide the Isolagen procedure. When reaching the United States, the company began its long approval process by the FDA. The current studies were conducted under a special protocol assessment by the FDA, which indicates that the FDA has agreed, in part, that successful results from the research could justify approval of the therapy.

COMPLICATIONS AND COST

Complication and expense of harvesting, storing and administering patients' own cells is the primary concern surrounding Isolagen's ultimate success. While taking a biopsy from the behind the ear to create the injection is simple, the overall cost of growing and multiplying the fibroblasts for its final destination causes concern. Isolagen treatment ranged from £2,500 to £5,000 when offered in the UK in 2002, and $4,000 per patient in the U.S. at last estimate (2004).

Yet, if a patient makes the investment upfront with a "full-face treatment," followed by a yearly treatment, the price is probably not going to be much different than receiving filler treatments three times a year, explains Mr. Daly.

"These issues are yet to be determined based on pricing and education of physicians and patients," says David H. McDaniel, M.D., F.A.A.D., director, Institute of Anti-Aging Research, Eastern Virginia Medical School, and assistant professor of Clinical Dermatology and Plastic Surgery, Eastern Virginia Medical School, Virginia Beach, Va. "The biopsy process is very simple and safe, and over the long term Isolagen will likely prove to be very cost effective because of it duration of benefits."

As for its "competition," both Mr. Daly and Dr. McDaniel agree that Isolagen should not be considered a competitor to fillers, but rather a nonsurgical alternative to peels and laser procedures.

"Fillers are primarily volumizers, whereas I view Isolagen more as 'replacement therapy.' That is, Isolagen is restoring or augmenting what was either lost or damaged from aging," says Dr. McDaniel, who is also co-director, Skin of Color Research Institute, Hampton University. "It may be competitive for some of the very fine-line fillers that have a short-lived effect, but predominantly this is a new tool for the cosmetic surgeon to add to his or her menu of therapies."

Using a 29-gauge needle, proper administration of Isolagen is technique sensitive, and training will be vital as it differs from administering injectable fillers, according to Dr. McDaniel. "However, this is simple to train and the biopsies are very easy — I do not foresee a significant problem overall."


Hide comments
account-default-image

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish